Generic Caprelsa Availability
CAPRELSA (vandetanib - tablet;oral)
Manufacturer: IPR PHARMS INC
Approval date: April 6, 2011
Strength(s): 100MG, 300MG [RLD]
Has a generic version of Caprelsa been approved?
No. There is currently no therapeutically equivalent version of Caprelsa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Caprelsa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Quinazoline derivatives as VEGF inhibitors
Issued: February 6, 2007
Inventor(s): Thomas; Andrew Peter & Stokes; Elaine Sophie Elizabeth & Hennequin; Laurent Francois Andre
Assignee(s): AstraZeneca AB
The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3 (wherein R3 is as defined hereinbefore); 3) C2-5alkynylR3 (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as a active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of number of disease states including cancer and rheumatoid arthritis.Patent expiration dates:
- August 14, 2021✓✓
- August 14, 2021
Pharmaceutical compositions comprising ZD6474
Issued: November 29, 2011
Inventor(s): Stott; Paul William
Assignee(s): AstraZeneca AB
A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.Patent expiration dates:
- August 8, 2028✓
- August 8, 2028
Quinazoline derivatives and pharmaceutical compositions containing them
Issued: May 10, 2011
Inventor(s): Thomas; Andrew Peter & Johnstone; Craig & Clayton; Edward & Stokes; Elaine Sophie Elizabeth & Lohmann; Jean-Jacques Marcel & Hennequin; Laurent Francois Andre
Assignee(s): AstraZeneca UK Limited
The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.Patent expiration dates:
- September 23, 2017✓✓
- September 23, 2017
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 6, 2016 - NEW CHEMICAL ENTITY
- April 6, 2018 - ORPHAN DRUG EXCLUSIVITY
- Caprelsa Consumer Information (Drugs.com)
- Caprelsa Consumer Information (Wolters Kluwer)
- Caprelsa Advanced Consumer Information (Micromedex)
- Caprelsa AHFS DI Monographs (ASHP)
- Vandetanib Consumer Information (Wolters Kluwer)
- Vandetanib Consumer Information (Cerner Multum)
- Vandetanib Advanced Consumer Information (Micromedex)
- Vandetanib AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|